Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.31 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27497292 | 0.80 | LMNA (0.36) | LMNAALDH1A1KDM4EUSP2AR | |
| SCHEMBL28489338 | 0.77 | LMNA (0.33) | LMNAALDH1A1KDM4EUSP2AR | |
| SCHEMBL8931433 | 0.77 | LMNA (0.34) | LMNAALDH1A1KDM4EUSP2AR | |
| SCHEMBL27561102 | 0.76 | LMNA (0.42) | LMNAALDH1A1CYP1A2KDM4EUSP2 | |
| SCHEMBL12972307 | 0.75 | KDM4E (0.45) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL15579377 | 0.75 | THRB (0.32) | LMNAALDH1A1THRB | |
| SCHEMBL116799 | 0.74 | MAPK1 (0.56) | LMNAALDH1A1CYP1A2KDM4EUSP2 | |
| SCHEMBL6269634 | 0.74 | LMNA (0.40) | LMNAALDH1A1CYP1A2KDM4EUSP2 | |
| SCHEMBL12083370 | 0.74 | MAPK1 (0.56) | LMNAALDH1A1CYP1A2KDM4EUSP2 | |
| SCHEMBL8083397 | 0.74 | MAPK1 (0.56) | LMNAALDH1A1CYP1A2KDM4EUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114086387-A | Graphene high-heat-dissipation fiber and preparation method thereof | 南通强生石墨烯科技有限公司 | 2022-02-25 | — | — | CN | claimed |
| CN-114086387-A | Graphene high-heat-dissipation fiber and preparation method thereof | 南通强生石墨烯科技有限公司 | 2022-02-25 | — | — | CN | disclosed |
| CN-111943841-A | Method for synthesizing functional food antioxidant ferulic acid dibutyl glyceride | 陕西国际商贸学院 | 2020-11-17 | — | — | CN | disclosed |
| US-20160130666-A1 | SIMULTANEOUS DETECTION OF MUTATIONAL STATUS AND GENE COPY NUMBER | VENTANA MEDICAL SYSTEMS, INC. | 2016-05-12 | — | — | US | disclosed |
| EP-2519825-B1 | SIMULTANEOUS DETECTION OF MUTATIONAL STATUS AND GENE COPY NUMBER | VENTANA MED SYST INC (US) | 2015-01-14 | — | — | EP | disclosed |
| EP-2519825-A1 | SIMULTANEOUS DETECTION OF MUTATIONAL STATUS AND GENE COPY NUMBER | Ventana Medical Systems, Inc. (US) | 2012-11-07 | — | — | EP | disclosed |
| US-20120264127-A1 | SIMULTANEOUS DETECTION OF MUTATIONAL STATUS AND GENE COPY NUMBER | VENTANA MEDICAL SYSTEMS, INC. | 2012-10-18 | — | — | US | disclosed |
| WO-2011082307-A1 | SIMULTANEOUS DETECTION OF MUTATIONAL STATUS AND GENE COPY NUMBER | VENTANA MEDICAL SYSTEMS, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| US-20090233803-A1 | CHROMOGENIC IN SITU HYBRIDIZATION METHODS, KITS, AND COMPOSITIONS | INVITROGEN CORPORATION (US) | 2009-09-17 | — | — | US | disclosed |
| US-20090137412-A1 | CHROMOGENIC IN SITU HYBRIDIZATION METHODS, KITS, AND COMPOSITIONS | INVITROGEN CORPORATION (US) | 2009-05-28 | — | — | US | disclosed |
| US-20080125358-A1 | Methods for Chk2 inhibitor patient selection | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL | 2008-05-29 | — | — | US | disclosed |
| EP-1434877-B1 | CHROMOGENIC IN SITU HYBRIDIZATION METHODS, KITS, AND COMPOSITIONS | ZYMED LAB INC (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20060035246-A1 | Chromogenic in situ hybridization methods, kits, and compositions | Life Technologies Corporation | 2006-02-16 | — | — | US | disclosed |
| US-6942970-B2 | Identifying subjects suitable for topoisomerase II inhibitor treatment | ZYMED LABORATORIES, INC. (US) | 2005-09-13 | — | — | US | disclosed |
| EP-1434877-A4 | CHROMOGENIC IN SITU HYBRIDIZATION METHODS, KITS, AND COMPOSITIONS | ZYMED LAB INC (US) | 2005-05-04 | — | — | EP | disclosed |
| EP-1434877-A2 | CHROMOGENIC IN SITU HYBRIDIZATION METHODS, KITS, AND COMPOSITIONS | Zymed Laboratories, Inc. (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20030134279-A1 | In situ hybridization probes and cancer therapy diagnostics | Life Technologies Corporation | 2003-07-17 | — | — | US | disclosed |
| WO-2003025127-A2 | CHROMOGENIC IN SITU HYBRIDIZATION METHODS, KITS, AND COMPOSITIONS | ZYMED LABORATORIES, INC. (US) | 2003-03-27 | — | — | WO | disclosed |
| US-20030017491-A1 | Chromogenic in situ hybridization methods, kits, and compositions | Life Technologies Corporation | 2003-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125358-A1 | Methods for Chk2 inhibitor patient selection | CHEK2, CHEK1, TP53 | LMNA 1664/4885ALDH1A1 3938/4885CYP1A2 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.